Infection Control by Antibody Disruption of Bacterial Quorum Sensing Signaling

Junguk Park, Reshma Jagasia, Gunnar F. Kaufmann, John C. Mathison, Diana I. Ruiz, Jason A. Moss, Michael M. Meijler, Richard J. Ulevitch, and Kim D. Janda

1Department of Chemistry
2Department of Immunology
3The Skaggs Institute for Chemical Biology
4The Worm Institute for Research and Medicine (WIRM)
The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
5These authors contributed equally to this work.

DOI 10.1016/j.chembiol.2007.08.013

SUMMARY

Quorum sensing (QS) is the process through which bacteria communicate utilizing small diffusible molecules termed autoinducers. It has been demonstrated that QS controls a plethora of microbial processes including the expression of virulence factors. Here we report an immunopharmacotherapeutic approach for the attenuation of QS in the Gram-positive human pathogen Staphylococcus aureus. An anti-autoinducer monoclonal antibody, AP4-24H11, was elicited against a rationally designed hapten, and efficiently inhibited QS in vitro through the sequestration of the autoinducing peptide (AIP)-4 produced by S. aureus RN4850. Importantly, AP4-24H11 suppressed S. aureus pathogenicity in an abscess formation mouse model in vivo and provided complete protection against a lethal S. aureus challenge. These findings provide a strong foundation for further investigations of immunopharmacotherapy for the treatment of bacterial infections in which QS controls the expression of virulence factors.

INTRODUCTION

The ability of microorganisms to coordinate their gene expression in a population density-dependent manner has been coined “quorum sensing” (QS) [1]. This chemical exchange of information among single-cell organisms is mediated by secreted signaling molecules termed autoinducers (AI) [2]. Bacterial autoinducers can be classified into three major chemical groups: (1) N-acyl homoserine lactones (AHLs) that have been shown to be produced by over 70 species of Gram-negative bacteria [3, 4], (2) oligopeptides, which are generally employed by Gram-positive bacteria [5, 6], and (3) the ribose-like S-4,5-dihydropyrazine-2,3-pentanedione (DPD)/autoinducer (Al)-2, which is utilized by both Gram-negative and -positive bacteria and, thus, can be regarded as an interspecies QS signaling molecule [7, 8].

Important biological and clinical aspects of QS include the regulation of bacterial virulence factors [9, 10], and hence inhibition of QS signaling could provide a promising new strategy for the attenuation of bacterial infections [11–13]. Indeed, small-molecule antagonists using AI analogs have been examined in a number of QS circuits as a means of signaling interference [14–18]. Alternatively, our laboratory pioneered an antibody-based strategy to inhibit AHL-mediated QS in Gram-negative bacteria [19]. Notably, following our initial report, an active immunization model in mice using an AHL-based vaccine was disclosed [20]. Ramifications arising from these studies have provided us further impetus to evaluate immunopharmacotherapeutic approaches targeting other bacterial QS systems.

Staphylococcus aureus is the most common cause of hospital-acquired infections [21] including various diseases ranging from skin infections and food poisoning to life-threatening nosocomial infections. Increasing resistance of S. aureus isolates to glycopeptide antibiotics, most prominently vancomycin, is a major concern in today’s intensive care units, and therefore an alternative strategy to combat this pathogen is urgently required. Accessory gene regulator (agr) is the best-characterized QS circuit in S. aureus. The agr system utilizes cyclic oligopeptides, termed autoinducing peptides (AIPs), and these contribute to bacterial pathogenesis by orchestrating the temporal cell density-dependent expression of virulence genes [22]. Genes regulated by agr encode cell-surface proteins such as protein A, coagulase, and fibronectin-binding proteins, and secreted proteins including proteases, hemolysins, toxic shock syndrome toxin 1 (TSST-1), and enterotoxin B.

In addition, the agr QS system has also been linked to resistance with glycopeptide antibiotics in S. aureus [23]. Notably, Novick and coworkers have demonstrated that transient inactivation of the agr QS circuit might indeed be sufficient to prevent the deleterious effects of certain S. aureus infections [24]. Thus far, four different AIPs, with varying degrees of sequence similarities, have been identified as agr QS molecules (Figure 1) [25]. As a starting point, we have designed a structure- and sequence-based approach to rationally design an immunogenic hapten for an antibody-based strategy to inhibit QS in S. aureus.
point for antibody-based interference with AIP-mediated QS, we focused on the AIP-4 QS system and its cognate strains RN4850 and NRS168 [16].

RESULTS AND DISCUSSION

Design and Synthesis of the AIP-4 Hapten

Based on the reported structural information of AIP-4 [26], we designed and synthesized the hapten AP4, 5 to elicit an anti-AIP-4 antibody immune response in mice (Figure 2). Our reasoning for the chemical switch from the native thiolactone to a lactone-containing hapten was based on a lactone’s greater aminolytic stability [27]. This strategy ensured that the hapten conjugates remained structurally intact during the immunization process and subsequent immune response, thus avoiding the generation of degradation products with unknown chemical and biological properties as previously uncovered for other QS molecules by our laboratory [28]. Furthermore, this substitution was also intended to prevent a possible intramolecular thiol exchange between the conserved thiolactone and the pendant cysteine thiol. Therefore, Fmoc-serine(Trt)-OH was incorporated at position 4 in place of the native cysteine residue.

The hapten 5 was conjugated to the carrier proteins keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA) via a bifunctional linker (see Figure S1 in the Supplemental Data available with this article online). BALB/c mice were immunized with the KLH conjugate using standard protocols [19]. Overall, the immunizations resulted in moderate titers (1600–3200) and, based on ELISA analysis, 20 monoclonal antibodies (mAbs) were prepared. The affinities of the AP4 mAbs were determined against all four natural AIPs using competition ELISA methodology (see Table S1). One of the mAbs, namely AP4-24H11, possessed strong binding affinity (K\textsubscript{d} AIP-4 ~ 90 nM) and high specificity to AIP-4 while displaying little crossreactivity for the other AIPs (K\textsubscript{d} AIP-1 ~ 5 \mu M, K\textsubscript{d} AIP-2 ~ 25 \mu M, K\textsubscript{d} AIP-3 ~ 25 \mu M). The ability of AP4-24H11 to discriminate between AIP-1 and AIP-4 is noteworthy, as these two oligopeptides differ only at position 5 with an aspartic acid residue in AIP-1 and a tyrosine moiety in AIP-4. Thus, AP4-24H11 was selected for further biological evaluation.

AP4-24H11 Alters Expression of Virulence Factors in S. aureus

\(\alpha\)-Hemolysin and protein A are two major virulence factors in S. aureus, and expression of these proteins is tightly regulated by S. aureus signaling networks including the AIP-based agr QS system. The agr QS system positively regulates expression of \(\alpha\)-hemolysin, whereas protein A production is downregulated by QS signaling. In order to test our rationale that anti-AIP antibodies are able to interfere with QS signaling in S. aureus, we examined whether...
the anti-AIP-4 mAb AP4-24H11 could modulate the expression of α-hemolysin and protein A in agr group IV strains RN4850 and NRS168. First, we observed that AP4-24H11 affects the expression and/or secretion of S. aureus exoprotoins, some of which might also be regulated by the agr QS circuits (see Figure S2A). As seen in Figure 3A, mAb AP4-24H11 can successfully reduce the α-hemolysin expression in S. aureus; furthermore, no hemolytic activity was observed on blood agar plates with the AP4-24H11-treated supernatant (Figure S2B). In contrast, protein A expression was significantly increased by mAb AP4-24H11 in RN4850, which is also consistent with agr QS inhibition.

The only structural difference between AIP-1 and AIP-4 is position 5, and our data suggest that AP4-24H11 is able to bind to AIP-1 with moderate affinity (= 5 μM). Therefore, we investigated whether AP4-24H11 could affect QS signaling in an agr group I strain, namely Wood 46. Clearly, AP4-24H11 was not able to block α-hemolysin expression in Wood 46 as effectively as in RN4850; however, a notable decrease in α-hemolysin production in Wood 46 grown in the presence of AP4-24H11 was evident (Figure 3A). These data suggest that it might be possible to generate crossreactive mAbs that suppress S. aureus QS signaling of two or more different agr groups.

Although it could be argued that the decrease in toxin production and overall protein secretion is caused by an antibody-mediated growth defect, it is important to note that no significant growth changes of S. aureus were observed over a 24 hr growth period in the presence of AP4-24H11 (Figure 3B). In addition, no discernable growth effects were observed with mAb SP2-6E11, an unrelated isotype control (κ72α) for AP4-24H11.

One of the important bacterial virulence factors regulated by QS is biofilm formation. In S. aureus, biofilm formation is known to be negatively regulated by agr QS signaling [29], which is indeed one of the problems in controlling S. aureus virulence through agr QS inhibition [30]. Consistent with previous studies, AP4-24H11-mediated QS inhibition led to increased biofilm formation in RN4850 (Figure 3C). Although the increase of biofilm formation poses a significant problem in chronic infection of S. aureus, it represents a lesser predicament in acute infections and, thus, mAb AP4-24H11 might still be an effective way to control such S. aureus infections.

Real-Time PCR Analysis
To further examine agr QS inhibition by AP4-24H11, we performed real-time polymerase chain reaction (real-time PCR) analysis to evaluate whether the observed changes in virulence factor expression were indeed caused by interference with the agr QS system, that is, whether the presence of AP4-24H11 affects the transcription of maliI, the immediate product of agr autoinduction and the main QS effector in S. aureus [31]. As expected, the maliI transcriptional level in RN4850 during stationary growth phase was reduced significantly (>50-fold) by AP4-24H11; this finding advocates that the alteration of α-hemolysin and protein A expression is a direct result of the interference of AIP-4-mediated QS signaling by AP4-24H11 (Figure 3D). Yet, the subtle changes in overall exoprotein expression (see Figure S2A) might be misconstrued to mean that AP4-24H11 does not block the QS signaling efficiently; however, our real-time PCR analysis provides evidence that AP4-24H11 significantly inhibits AIP-4-based QS in S. aureus RN4850.

To gain greater appreciation of the specificity and potential limitations of antibody-based QS interference in S. aureus, we investigated the transcriptional level of two additional virulence regulators, namely sarA (staphylococcal accessory regulator) and saeR (staphylococcal accessory protein effector) [6, 32, 33], which control the response to environmental stresses as well as virulence factor expression in S. aureus. Importantly, no significant changes (≤2-fold) were observed in either sarA or saeR transcription, supporting that AP4-24H11 only affects the agr QS system (Figure 3D).

The transcription of α-hemolysin and protein A was analyzed by real-time PCR. As stated (vide supra), significant changes were seen in protein expression level. In terms of transcription, the hla and spa genes were suppressed and elevated, respectively, ~3- to 5-fold, again confirming that maliI affects not only transcription but also translation of these proteins, as reported previously [31]. Finally, exfoliatin A (eta) transcription was investigated, which is another agr QS-regulated toxin exclusively produced by AIP-4 utilizing S. aureus strains [34]. Gratifyingly, our data indicated that AP4-24H11 also decreased eta transcription by ~10-fold (Figure 3D).

Inactivation of AP4-24H11 by the Synthetic AIP-4
Balaban and coworkers have proposed that the RNAIII-activating protein (RAP) regulates agr QS signaling in S. aureus in an AIP-independent manner [35]. In addition, the same group has reported that a linear peptide, termed RNAIII-inhibiting peptide (RIP), could blunt RAP-mediated QS signaling, resulting in a decrease in RNAIII transcription, although it is still debatable [36, 37]. Although we have presented evidence that AP4-24H11 inhibited agr QS through binding to AIP-4 and sequestering it from the cell growing medium, there was still the possibility that AP4-24H11 might affect other signaling systems in S. aureus including RAP, which in turn could affect the agr QS network. As such, we investigated whether external addition of AIP-4 could restore the agr QS signaling network in S. aureus RN4850 in the presence of AP4-24H11. Thus, we treated AP4-24H11 with an equimolar amount of synthetic AIP-4 before addition to the S. aureus growth medium; this then would assure saturation of the antibody binding sites with the AIP-4 peptide. As seen in Figure 3E, the addition of synthetic AIP-4 efficiently reduced the quorum quenching effect of AP4-24H11, and as a result fully restored expression of α-hemolysin in S. aureus RN4850. As expected, this finding provides additional confirmation that AP4-24H11 indeed sequesters AIP-4 in S. aureus growth medium and inhibits AIP-dependent QS signaling in S. aureus in a strictly AIP-4-dependent manner.
AP4-24H11 Inhibits S. aureus-Induced Apoptosis in Mammalian Cells

Recent studies have shown that incubation of Jurkat T cells with supernatant of S. aureus culture results in induction of apoptosis [38]. We treated Jurkat cells with the supernatants of S. aureus (RN4850 and Wood 46) cultures grown in the presence or absence of AP4-24H11. After incubation for 4 hr with the supernatant, the cleavage of poly(ADP-ribose) polymerase (PARP), a biochemical marker indicative of apoptosis induction, was evaluated in Jurkat cell protein extracts. As shown in Figure 3, AP4-24H11 prevented RN4850 supernatant (1%) to induce PARP cleavage in Jurkat cells, and also partially inhibited the effect of Wood 46 supernatant. In fact, previous mechanistic studies proposed that one of the major factors in S. aureus supernatant responsible for inducing apoptosis might be α-hemolysin; our findings (Figures 3A and 4), support this positive correlation between expression of α-hemolysin and S. aureus-induced apoptosis.

AP4-24H11 Blocks S. aureus-Induced Dermal Injury in Mice

Next, we investigated the potential of mAb AP4-24H11 to mitigate S. aureus-induced injury in vivo by employing a murine subcutaneous infection model. Freshly grown log phase S. aureus RN4850 was suspended in PBS containing Cytodex beads and, where indicated, AP4-24H11 or control IgG. Subcutaneous injections of bacterial suspension or vehicle control were made in the flank of SKH1 hairless mice followed by close monitoring over 7 days. Doses administered were 10^7 or 10^8 bacteria (colony forming units; cfu) and 0.6 or 0.06 mg AP4-24H11 or control IgG. Mice receiving 10^7 cfu developed minimal hyperemia/edema followed by limited induration over 7 days...
However, as early as 6 hr after injection, mice receiving $10^8$ cfu suspended in saline or control IgG showed early-stage hyperemia/redness at the injection site and extending 3–5 mm horizontally and 5–10 mm vertically in a diagonal pattern along the flank (Figure 5A). Upon reexamination at 18 hr, the same areas surrounding the injection site were devitalized, and the skin was transformed to a brittle, reddish-brown scab. Over the 7 day observation period, the hardened scab began to detach from the surrounding relatively normal appearing skin, and small amounts of purulent exudate were observed at the normal/necrotic junction. In contrast, skin injury was abrogated in mice that received $10^8$ bacteria with 0.6 mg AP4-24H11 (Figure 5C). As anticipated, the lower dose of AP4-24H11 (0.06 mg) was not protective (Figure 5B), and control mice receiving $10^8$ cfu with 0.6 mg control IgG were not protected (see Figure S3B). Mice that received an injection of PBS/Cytodex alone or containing 0.6 mg AP4-24H11 remained normal over the observation period with the exception of occasional local induration (Figure 5D). Excitingly, animals that had received the protective dose of 0.6 mg AP4-24H11 in combination with $S. aureus$ RN4850 did not develop any significant lesions over the 7 day observation period.
followed 2 hr later by 0.5 ml DPBS/C0 vehicle (Dulbecco’s phosphate-buffered saline; DPBS) peritoneal (i.p.) injection of AP4-24H11, control IgG, or mostly for cancer immunotherapy[39]. However, anti-
third of the molecules undergoing clinical evaluation, of the organism. Antibodies now comprise over one from bacterial culture without genetic manipulations establishes this as the first report of AIP removal in infancy[39–41]. Conventional QS interference strategies utilizing small-molecule antagonists are based on a competition between the bacterial autoinducer and the inhibitor for the bacterial AI receptor protein. In contrast, quorum quenching antibodies engage in competition with the AI receptor for the autoinducer. In this context, an immunopharmacotherapeutic strategy is highly appealing, as the antibody acts as a “decoy-receptor” while possessing well-documented pharmacokinetic behavior and pharmacodynamic response.

In total, antibodies generated against bacterial autoinducers represent a new and valuable set of immunological tools for both the study of QS-controlled processes and potentially an alternative strategy engaging immunopharmacotherapy for the prevention or treatment of infections in which QS signaling contributes to bacterial pathogenesis.

**EXPERIMENTAL PROCEDURES**

**Synthesis of the Linear Protected Peptide 3**

All N-α-Fmoc-protected amino acids, coupling reagents, and resins for peptide synthesis were purchased from EMD Biosciences (San Diego, CA, USA). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). ESI-MS analyses were performed with API150EX (PE SCIEX, Foster City, CA, USA), and Hitachi L-7300 (Hitachi, San Jose, CA, USA) and Shimadzu SCL-10A (Shimadzu, Columbia, MD, USA) were used for analytical and preparative HPLC experiments, respectively.

The peptide was synthesized by Fmoc solid-phase peptide synthesis on 2-chlorotrityl resin preloaded with the Fmoc-Met 1. An Fmoc-Ser(TriT)-OH was incorporated at the position of lactonization. All other residues were chosen with side-chain protecting groups stable to dilute TFA and labile at 95% TFA. A short flexible linker was incorporated penultimate to the N terminus by coupling Fmoc-8-amino-3,6-dioxo-acontic acid. The N-terminal residue was Boc-Cys(SET)-OH for eventual use in conjugation to carrier proteins.**Specific Conditions**

Batch synthesis was carried out on 1 mmol resin swollen in DMF for at least 1 hr. A solution of the protected amino acid, N,N-diisopropylcarbodiimide (DIC), and HOBT (4 equivalents each) in 5 ml DMF was prepared and allowed to sit for 5 min for preactivation, followed by the addition of 0.5 ml sym-collidine. The cocktail was added to the resin for coupling, which was generally complete in 1 hr. The resin was then washed with DMF and subjected to Fmoc deprotection with 20% (v/v) piperidine in DMF (2 × 7 min). The resin was then washed with DMF and the next coupling reaction was carried out. When synthesis was complete, the resin was washed with DMF, then methylene chloride, and finally with ether before it was placed in a desiccator.

**Cleavage (and Trityl Deprotection)**

The resin was added to a cocktail of 4% TFA, 4% trisopropylsilane (TIS), and 0.5% H2O in chloroform, and shaken for 6 hr. The mixture was filtered, allowing the filtrate to drip into cold ether to precipitate the peptide. The ether mixture was centrifuged and the supernatant was decanted. The peptide was then washed (twice) with ether by repeatedly suspending the solid in ether, centrifuging, and decanting the supernatant. The resulting solid was dissolved in methylene chloride and finally with ether before it was placed in a desiccator.

**Purification**

The fully protected peptide 3 was dissolved in methylene chloride and purified by normal-phase silica gel chromatography eluted with 5% methanol in methylene chloride.

**Lactonization of 3**

The protected linear peptide 3 was dissolved in 1,2-dichloroethane (previously dried over anhydrous MgSO4) to give a final concentration of no greater than 1.0 mM. The solution was stirred and heated to 80°C and 3 equivalents each of 1-ethyl-3-(3-dimethylaminopropyl)-

We have sought to elucidate the consequences of quorum sensing signaling using highly specific anti-autoinducer antibodies elicited against a rationally designed synthetic hapten. Our data indicate that the scavenging of an AIP by a monoclonal antibody is sufficient to suppress QS-controlled expression of virulence factors in S. aureus, which to our knowledge establishes this as the first report of AIP removal from bacterial culture without genetic manipulations of the organism. Antibodies now comprise over one-third of the molecules undergoing clinical evaluation, mostly for cancer immunotherapy[39]. However, antibody-based therapies for the treatment of bacterial infections using QS as a molecular target are still in their infancy [39–41]. Conventional QS interference strategies utilizing small-molecule antagonists are based on a competition between the bacterial autoinducer and the inhibitor for the bacterial AI receptor protein. In contrast, quorum quenching antibodies engage in competition with the AI receptor for the autoinducer. In this context, an immunopharmacotherapeutic strategy is highly appealing, as the antibody acts as a “decoy-receptor” while possessing well-documented pharmacokinetic behavior and pharmacodynamic response.

In total, antibodies generated against bacterial autoinducers represent a new and valuable set of immunological tools for both the study of QS-controlled processes and potentially an alternative strategy engaging immunopharmacotherapy for the prevention or treatment of infections in which QS signaling contributes to bacterial pathogenesis.

**SIGNIFICANCE**

To evaluate the effectiveness of a passive immunization approach using AP4-24H11 against a lethal challenge with S. aureus, SKH1 hairless mice received a 1 ml intraperitoneal (i.p.) injection of AP4-24H11, control IgG, or vehicle (Dulbecco’s phosphate-buffered saline; DPBS) followed 2 hr later by 0.5 ml DPBS− containing 3 × 108 S. aureus RN4850. As shown in Figure 6, all of the mice receiving AP4-24H11 (6/6) survived through the 8 day observation period. In contrast, only one of the DPBS-treated control mice (1/6) and none of the control IgG-treated mice (0/6) survived longer than 24 hr. These data further validated our immunopharmacotherapeutic approach for combating acute S. aureus infections.

**Figure 6. Passive Immunization of Mice with AP4-24H11 against S. aureus Infection**

Survival in mice that were pretreated with mAb AP4-24H11 or control IgG followed 2 hr later by S. aureus injection (3 × 108 i.p.). The numbers in parentheses show the number of survivors/number per group. Log rank statistic, p = 0.001; n = 6 for each group.

**Passive Immunization with AP4-24H11 Protects Mice from S. aureus-Induced Fatality**

The protected linear peptide 3 was dissolved in 1,2-dichloroethane (previously dried over anhydrous MgSO4) to give a final concentration of no greater than 1.0 mM. The solution was stirred and heated to 80°C and 3 equivalents each of 1-ethyl-3-(3-dimethylaminopropyl)-...
carbodiimide hydrochloride (EDC) and 4-dimethylaminopyridine (4-DMAP) were added; another equivalent each of EDC and 4-DMAP were added at both 24 and 48 hr into the reaction. The reaction was monitored by HPLC. After 4 days, the reaction mixture was cooled to room temperature, washed with 2 × 200 ml of 0.2 M KHSO4 (aqueous), dried over anhydrous Na2SO4, and evaporated to dryness. The cyclized peptide 4 was purified by prep-HPLC. Yields ranged from 30%–60% as determined by analytical HPLC integration.

Global Deprotection and Disulfide Deprotection of 4

The solid, purified peptide was dissolved in TFA containing 2% TIS and stirred for 1 hr. The mixture was then evaporated to dryness. Water was added and the mixture was frozen and lyophilized. The lyophilized solid was then dissolved in H2O with tris(2-carboxyethyl)phosphine hydrochloride (TCEP). The mixture was stirred for 1 hr and injected directly into the prep-HPLC for purification, yielding AP4 hapten 5. The collected pure fractions were pooled, frozen, and lyophilized. ESI-MS: m/z calculated for C56H70N10O12S2 (M + H)+, 1241.5; found, 1242.2.

Conjugation of 5 to KLH/BSA

Attachment of Sulfo-SMCC

Five milligrams of the carrier protein was resuspended in 0.9 ml PBS (pH 7.4). To this solution was added 1 mg of the linker sulfo-SMCC (sulfosuccinimidyl 4-[N-maleimidomethyl]-cycllohexane-1-carboxylate). The solution was stirred for 6–8 hr and the protein-linker conjugate was purified by dialysis in PBS at 4°C.

Conjugation of the Hapten 5

To the protein-linker conjugate in PBS was added 100 μl DMF containing 2 mg of the hapten 5. The solution was shaken overnight and the protein-hapten conjugate was purified by dialysis. MALDI-TOF analysis confirmed the attachment on average of 6 hapten per BSA molecule.

Analysis of Exoprotein Secretion in S. aureus

After overnight growth on an agar plate at 37°C, a single colony of S. aureus (RN4850 or Wood 48) was inoculated into 3 ml CYGP medium and grown overnight (18 hr) [42]. The overnight cultured cells were diluted to OD600 = 0.03 in fresh CYGP medium, and distributed to 5 ml polystyrene cell-culturing tubes, where each tube contained 0.5 ml of the diluted cells and the appropriate antibody (0.2 mg/ml). After growth for 20–24 hr at 37°C in a humid incubator without agitation, the samples were transferred to microcentrifuge tubes (1.5 ml) and centrifuged at 13,000 rpm for 5 min. The supernatants were sterilized by filtration through a Millex-GV filter unit (0.22 μm; Millipore, Billerica, MA, USA) and analyzed by SDS-PAGE (10% bis-Tris gel; Invitrogen, Carlsbad, CA, USA). To confirm α-hemolysin and protein A expression, western blot analyses were performed using an HRP-conjugated sheep polyclonal α-hemolysin antibody (Abcam, Cambridge, MA, USA) and anti-protein A mouse monoclonal antibody (Sigma-Aldrich), and murine mAb SP2-6E11 (J.P. and K.D.J., unpublished data) was used as a control antibody. To test hemolytic activity, the S. aureus supernatants (75 μl × 3) were applied onto the sheep blood agar plate, and the plates were incubated at 37°C for 18 hr and at room temperature for another 24 hr.

Static Biofilm Analysis

The biofilm assay was conducted by following a literature procedure with a few modifications [43]. After S. aureus were grown in tryptic soy broth medium containing 0.2% glucose with or without the antibody (0.2 mg/ml) in the polystyrene 96-well plate for 20–24 hr without agitation, the plate was washed by submersion in water and dried. A crystal violet solution (200 μl, aqueous 0.1%) was added to stain the biofilm, and then the plate was washed vigorously with water followed by the addition of acetic acid (250 μl, aqueous 30%) to solubilize the remaining crystal violet. Absorbance was measured at 570 nm with a SpectraMax 250 (Molecular Devices, Sunnyvale, CA, USA).

Real-Time PCR Analysis

Overnight cultured S. aureus RN4850 cells were diluted to OD600 = 0.03 in fresh CYGP medium (1 ml) containing the antibody and grown for 20–24 hr (OD600 = 2) at 37°C without shaking. RNA from the cells was isolated using an RNeasy mini kit (QIAGEN, Valencia, CA, USA) according to the manufacturer’s instructions. Isolated RNA was further purified by treating with RNase-free DNase (QIAGEN) for 30 min at room temperature. The first-strand DNA was synthesized using the SuperScript First-Strand synthesis system for real-time PCR (Invitrogen) using ~300 ng of purified RNA. Real-time PCR experiments were performed with at least two independent samples, and each experiment was set up in duplicate using LightCycler FastStart DNA MasterPLUS SYBR Green I (Roche Applied Science, Indianapolis, IN, USA). Generic SYBR Green Protocol (Roche) was used for the PCR conditions, and relative quantification analyses were performed with a LightCycler 2.0 system (Roche Applied Science) using the housekeeping gyrA gene as a reference. The sequence information of the primers used in our experiments is listed in Supplemental Data [44].

Dermal Infection Model in Mice

All experiments on mice were performed in accordance with TSRI guidelines and regulations. SKH1 euthymic hairless mice, 6–8 weeks old, were obtained from Charles River Laboratories (Wilmington, MA, USA) and housed in the bioc containment vivarium for 1 week before use in experiments. Brain heart infusion (BHI) agar was from BBL (Sparks, MD, USA; 211065), and CYGP broth contained 1% casamino acids (Fisher, Pittsburgh, PA, USA; BP1424), 1% yeast extract (EMD Biosciences, San Diego, CA, USA; 1.03753), 0.59% sodium chloride, 0.5% dextrose, and 60 mM β-glycerolphosphate disodium salt (Fluka, Milwaukee, WI, USA; 50020) as described by Novick [43]. Cytodex 1 beads (GE Healthcare, Piscataway, NJ, USA; 17-0448-01) were suspended (1 g in 50 ml) in Dulbecco’s phosphate-buffered saline without calcium/magnesium ( Gibco Invitrogen) overnight at 20°C. The supernatant was decanted and the beads were washed three times by suspension in DPBS and 1G sedimentation followed by autoclaving (121°C, 15 psi, 15 min). Staphylococcus aureus RN4850 (AIP-4) was grown from frozen stock (BHI + 20% glycerol) on BHI agar plates at 35°C overnight. Three representative colonies were combined to inoculate 2 ml CYGP broth, and after overnight incubation without shaking, 0.25 ml of the culture was used to inoculate 5 ml of CYGP followed by incubation at 35°C. 200 rpm for 3 hr. The culture was centrifuged at 1300 × g at 4°C for 20 min, the supernatant was poured off, and the bacterial pellet was suspended in 1 ml DPBS without calcium/magnesium. The SKH1 mice received 200 μl intradermal flank injections containing S. aureus (1 × 109 or 1 × 108 bacteria), 4 μl packed volume Cytodex beads, DPBS, and anti-AIP-4 antibody or control IgG (0.6 or 0.06 mg). Additional control animals received 200 μl intradermal injections containing Cytodex beads or beads plus antibody. After the injections were made, the mice were monitored at least three times each day over a period of 4–7 days. At the conclusion of the monitoring period, the mice were euthanized and the tissues were harvested for bacteriologic and histologic analysis.

Passive Immunization of Mice with AP4-24H11

S. aureus RN4850 were stored at ~80°C in 20% glycerol/BHI medium, thawed, and grown on BHI agar plates overnight, and three separate colonies were sampled to inoculate 2 ml CYGP medium. The inoculum culture was maintained 1 hr at 35°C without shaking, followed by shaking at 200 rpm for 3 hr. Aliquots of the freshly grown inoculum culture were transferred to 5 ml CYGP medium in 50 ml conical polypropylene tubes (1/20 dilution) followed by shaking at 200 rpm, 35°C for 3 hr. The bacteria were pelleted by centrifugation at 3000 rpm (1300 × g) for 10 min, 4°C. The bacterial pellets were resuspended in Dulbecco’s phosphate-buffered saline without calcium/magnesium (DPBS) and enumerated using a Petroff-Hauser counting chamber. Final dilutions were made in DPBS so that 3 × 108 bacteria were administered i.p. in 0.5 ml. To maintain viability, bacteria were administered within 2 hr of harvest.
mAb AP4-24H11, isotype-matched control IgG (1 mg each), or DPBS was administered i.p. in DPBS to SKH1 mice (6–9 weeks old; six animals per treatment group) followed 2 hr later by 0.5 ml DPBS i.p. containing 3 × 10^6 S. aureus. The mice were monitored several times on the day of injection and twice each day on subsequent days, observing ambulation, alertness, response to handling, and skin temperature measured by infrared thermometry (Raytek Mini-Temp MT4; Santa Cruz, CA, USA) using a 1 cm diameter infrasternal skin site. Animals showing surface temperature consistently below 30 °C and also diminished response to handling and weakened righting reflex were considered moribund and were euthanized.

**Other Experimental Procedures**

See the Supplemental Data for details of syntheses of AIPs (also see Figure S4), competition ELISA, and sequence information of the primers for real-time PCR.

**Supplemental Data**

Supplemental Data include four figures, one table, and Supplemental Experimental Procedures and can be found with this article online at http://www.chembioi.com/cgi/content/full/14/10/1119/DC1/.

**ACKNOWLEDGMENTS**

We are grateful to Dr. Richard P. Novick (Skirball Institute, New York University Medical Center) for the generous gift of RN4850. We also thank the TSRI Antibody Production Core Facility for providing the purified monoclonal antibodies. A clinical isolate, NRS168, was obtained through the Network on Antimicrobial Resistance in Staphylococcus aureus (NARS) program supported by the NIAID/NH (NO1-AI-95359). This work was supported by the National Institutes of Health (AI055778 to K.D.J.) and The Skaggs Institute for Chemical Biology. The authors declare no competing financial interests.

Received: June 20, 2007
Revised: August 10, 2007
Accepted: August 15, 2007
Published: October 26, 2007

**REFERENCES**


